Recent Updates — PLUR
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX, granting an exclusive U.S. license to its regenerative medicine portfolio in exchange for 41% of ZEO’s equity, Series D preferred stock, and warrants. Pluri will hold board nomination rights and aim for a 50% ownership stake. Separately, the company raised $1 million by issuing common shares and warrants at $1.10 per share to two investors. Additionally, the EIB sold its €27.5 million loan to shareholder Alexandre Weinstein at a discount, with settlement terms pending. Pluri Inc. operates in the biotechnology sector, developing regenerative medicine therapies.
Pluri Inc. issued 833,334 common shares at $1.50 per share and a warrant to buy an equal number of shares at $1.65 exercise price to Chutzpah Holdings LP, the company's largest shareholder and board chairman. The $1.25 million previously paid as an advance subscription fee was applied in full toward this transaction. The warrant becomes exercisable six months after issuance and expires five years after initial exercise. Pluri Inc. develops advanced technology solutions for industrial applications.
Pluri Inc. entered into a securities purchase agreement on August 26, 2026, for a registered direct offering of 1,200,000 common shares and pre-funded warrants to purchase up to 1,028,940 additional shares. The transaction includes a concurrent private placement of common warrants exercisable at $1.65 per share for 2,228,940 total shares. Net proceeds are expected to be approximately $2,984,808 after fees and expenses. The offering is expected to close on August 28, 2026. Pluri Inc. operates in the advanced technology sector, specializing in semiconductor manufacturing equipment.
Pluri Inc.'s indirect majority-owned subsidiary, Ever After Foods Ltd., entered into a share purchase agreement to acquire Fishway BV and its shareholders. The transaction involves issuing EAF ordinary shares in exchange for all outstanding Fishway capital, alongside a $2.0 million Simple Agreement for Future Equity (SAFE) investment from certain sellers. Pluri Inc. is not a party to the agreements but currently holds approximately 69% of EAF; post-closing, its indirect stake is expected to dilute to roughly 58%. The deal aims to support EAF's European strategy through Fishway's Belgian presence and cultivated seafood research capabilities. Closing is anticipated within 30 days subject to customary conditions. Pluri Inc. operates in the biotechnology sector, developing cellular agriculture technologies for food production.
Pluri Inc. is in active discussions with the European Investment Bank (EIB) regarding a potential resolution for its €50 million finance agreement, which was scheduled to be repaid on June 1, 2026. The EIB has indicated that discussions are advancing constructively and are subject to its internal approval process and legal review. Pluri Inc. operates in the biotechnology/cell therapy industry and develops cell-based products for therapeutic and therapeutic-related applications.
Pluri Inc. received a written notice from Nasdaq indicating it is not in compliance with the minimum market value of listed securities requirement of $35 million. The company has an initial 180-day compliance period ending January 4, 2027, to regain compliance. Pluri Inc. is a biotechnology company that develops cell-based products for the medical and food industries.